IL1B and myocardial infarction: ,13–15 Recently, the CANTOS trial showed that targeted cytokine inhibition (IL-1β inhibition with Canakinumab) in CAD patients with a prior myocardial infarction and residual inflammatory risk reduced further cardiovascular events.16